Malaria

We are pursuing pyronaridine as a single agent treatment based on already completed clinical studies performed by others. We have an orphan drug designation and rare pediatric disease designation for this disease.

We have also developed novel pyronaridine analogs with comparable activity across Plasmodium falciparum and drug resistant strains with collaborators.